Investor Overview

DBV Technologies is developing the VIASKIN^® patch, an investigational proprietary technology with broad potential clinical applications. The VIASKIN^® patch is based on epicutaneous immunotherapy, or EPIT, a method of delivering biologically active compounds to the immune system through intact skin. With this new class of patch-based, non-invasive product candidates, the Company is dedicated to safely transforming the care of food-allergic patients. DBV’s food allergy programs include ongoing clinical trials of the VIASKIN^® peanut patch in children. In addition to food allergies, the VIASKIN^® patch technology is also being investigated as a treatment option for other immunological disorders. Additional applications for the VIASKIN^® patch, such as a non-invasive method for delivering vaccines against certain diseases, are also being investigated. DBV Technologies has global headquarters in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one ordinary share) are traded on the Nasdaq Stock Market (Ticker: DBVT).